此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项测试 BI 771716 是否可以帮助患有晚期年龄相关性黄斑变性 (AMD)(称为地理萎缩)的患者的研究 (VERDANT)

2026年11月11日 更新者:Boehringer Ingelheim

随机、双盲、主动对照、多中心研究,评估两种玻璃体内注射 BI 771716 治疗方案针对继发于年龄相关性黄斑变性继发性地理萎缩的受试者的有效性和安全性 VERDANT 试验

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.

In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.

Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.

研究概览

研究类型

介入性

注册 (实际的)

202

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Gilbert、Arizona、美国、85297
        • Associated Retina Consultants
      • Phoenix、Arizona、美国、85020
        • Associated Retina Consultants, Ltd.
      • Phoenix、Arizona、美国、85050
        • Phoenix Retina Associates
      • Scottsdale、Arizona、美国、85255
        • Retina Macula Institute of Arizona
    • California
      • Glendale、California、美国、91204
        • Global Research Management
      • Huntington Beach、California、美国、92647
        • Retina Associates of Southern California
      • Modesto、California、美国、95356
        • Retinal Consultants Medical Group, Inc
      • Newport Beach、California、美国、92663
        • Eye Research Foundation
      • Poway、California、美国、92064
        • Retina Consultants of San Diego
      • Sacramento、California、美国、95825
        • Retinal Consultants Medical Group
      • Walnut Creek、California、美国、94598
        • Bay Area Retina Associates - Walnut Creek
    • Colorado
      • Lakewood、Colorado、美国、80228
        • Colorado Retina Associates
    • Connecticut
      • Danbury、Connecticut、美国、06810
        • Connecticut Eye Consultants, PC
      • Waterford、Connecticut、美国、06385
        • Retina Group of New England, PC
    • Florida
      • Deerfield Beach、Florida、美国、33064
        • Rand Eye Institute
      • Fort Lauderdale、Florida、美国、33308
        • Retina Group of Florida
      • Pinellas Park、Florida、美国、33782
        • Eye Associates of Pinellas
      • St. Petersburg、Florida、美国、33711
        • Retina Vitreous Associates of Florida
    • Georgia
      • Augusta、Georgia、美国、30909
        • Southeast Retina Center, PC
    • Illinois
      • Lemont、Illinois、美国、60439
        • University Retina and Macula Associates
      • Oak Park、Illinois、美国、60304
        • Illinois Retina Associates - Oak Park
    • Kentucky
      • Louisville、Kentucky、美国、40206
        • Butchertown Clinical Trials
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Ophthalmic Consultants of Boston
    • Minnesota
      • Edina、Minnesota、美国、55435
        • Retina Consultants of Minnesota
    • Mississippi
      • Madison、Mississippi、美国、39110
        • Mississippi Retina Associates
    • Missouri
      • Columbia、Missouri、美国、65212
        • University of Missouri Health System
    • New Jersey
      • Bloomfield、New Jersey、美国、07003
        • Envision Ocular, LLC
    • New Mexico
      • Albuquerque、New Mexico、美国、87109
        • Eye Associates of New Mexico
    • New York
      • Westbury、New York、美国、11590
        • Long Island Vitreoretinal Consultants - Westbury
    • Oregon
      • Eugene、Oregon、美国、97401
        • Verum Research, LLC
    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18017
        • Mid Atlantic Retina - Bethlehem
    • South Carolina
      • Charleston、South Carolina、美国、29414
        • Charleston Neuroscience Institute - Charleston
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Tennessee Retina
    • Texas
      • Austin、Texas、美国、78750
        • Austin Clinical Research, LLC
      • Beaumont、Texas、美国、77707
        • Retina Consultants of Texas - Beaumont
      • Bellaire、Texas、美国、77401
        • Retina Consultants of Texas-Bellaire-67493
      • Dallas、Texas、美国、75231
        • Retina Foundation of the Southwest
      • Katy、Texas、美国、77494
        • Retina Consultants of Texas - Katy
      • Plano、Texas、美国、75024
        • Red River Research Partners, LLC
      • San Antonio、Texas、美国、78240
        • Retinal Consultants of San Antonio
      • Schertz、Texas、美国、78154
        • Retina Consultants of Texas - Schertz
      • The Woodlands、Texas、美国、77384
        • Retina Consultants of Texas-The Woodlands-67575
    • Utah
      • Salt Lake City、Utah、美国、84107
        • Retina Associates of Utah
    • Virginia
      • Lynchburg、Virginia、美国、24502
        • Piedmont Eye Center
    • Washington
      • Spokane、Washington、美国、99204
        • Spokane Eye Clinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria

  • Age at least 50 years old at the time of randomization visit

  • Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

  • Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use are provided in the participant information. Male participants must be ready and able to use either a condom or abstinence as contraceptive measures

  • Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), where the total GA lesion area must be ≥2.5 square millimetres (mm²) and ≤17.5 mm² as measured by Fundus autofluorescence (FAF)

    • If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥1.25 mm²
    • Note: Fellow eye is not required to have GA
    • Note: subfoveal GA lesions (defined as GA lesions within 1 micron of the foveal center point) will be allowed to be enrolled until a maximum of approximately 60% of participants with subfoveal GA lesions are enrolled. Participants with subfoveal GA lesions already in screening at the time the cap has been reached may be considered for randomization.
  • Fellow eye must have sufficient visual function compared to the study eye, per the investigator's medical judgment in consultation with the patient, to support the patient's daily functioning

  • BCVA letter score of ≥24 letters, using the ETDRS chart in the study eye (equivalent to ≥20/320 on the Snellen chart). Note: If both eyes meet eligibility criteria, the eye with the worse visual function per the investigator's medical judgment in consultation with the patient, will be selected as the study eye. If both eyes have similar visual function, the study eye will be selected per the investigator's medical judgment in consultation with the patient

  • further inclusion criteria apply

Exclusion criteria

  • GA lesions whose area cannot be accurately defined in the study eye

  • Exudative neovascular AMD (eAMD) in the study eye

    -- Note: eAMD in the fellow eye is allowed. However, if the fellow eye is to be considered for microperimetry and other analyses (as defined in the trial statistical analysis plan), then eAMD is not allowed in either eye.

  • Previously received treatment in the study eye for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer

  • Previously received an investigational medication (oral or intravitreal) for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer

  • Currently enrolled in another investigational device or drug trial, or 30 days or 5 half-lives, whichever is longer since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Any previous use of gene therapy or cell therapy is not permitted

  • Additional eye disease as follows:

    • Any eye disease in the study eye that could compromise BCVA
    • Uncontrolled glaucoma or ocular hypertension with intraocular pressure >24 millimetre of mercury (mmHg) in study eye
    • History of high myopia >8 diopters in the study eye
    • Anterior segment and vitreous abnormalities that would preclude adequate observation with spectral domain optical coherence tomography in the study eye
    • Ocular conditions at the discretion of the investigator that might interfere with outcome of the trial in the study eye
    • Active intraocular inflammation in the study eye
    • Active infectious conjunctivitis in either eye
  • Prior vitrectomy surgery in the study eye

  • History of major intraocular surgeries including major corneal surgery. Uneventful cataract surgery, refractive surgery, oculoplastic surgery, strabismus surgery, and other extraocular surgery may be permitted if they have occurred more than 3 months prior to baseline in the study eye

  • further exclusion criteria apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:A 臂:BI 771716

BI 771716

实验性的:B 组:BI 771716 和假比较器

BI 771716

Sham comparator to BI 771716

有源比较器:C臂:Pegcetacoplan

Pegcetacoplan

其他名称:
  • 赛福尔®

研究衡量的是什么?

主要结果指标

结果测量
大体时间
通过研究眼中的眼底自发荧光 (FAF) 测量的平方根转化地理萎缩 (GA) 面积相对于基线的变化斜率,以毫米 (mm)/年表示
大体时间:第 56 周的基线
第 56 周的基线

次要结果测量

结果测量
大体时间
通过 FAF 在研究眼中测量的平方根转化 GA 面积相对于基线的变化(以 mm 表示)
大体时间:第 56 周的基线
第 56 周的基线
通过标准化早期试验糖尿病视网膜病变研究 (ETDRS) 图表测量研究眼的最佳矫正视力 (BCVA) 相对于基线的变化
大体时间:第 56 周的基线
第 56 周的基线
通过至少 2 次连续就诊的研究眼中标准化 ETDRS 图测量,BCVA 字母丢失≥15 个字母的发生情况
大体时间:直至第 56 周
直至第 56 周
从首次给药至第 56 周,研究眼中渗出性新生血管性年龄相关性黄斑变性 (eAMD) 的发生情况
大体时间:直至第 56 周
直至第 56 周
从首次给药至第 56 周药物相关不良事件 (AE) 的发生情况
大体时间:直至第 56 周
直至第 56 周

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月6日

初级完成 (实际的)

2026年10月26日

研究完成 (实际的)

2026年10月26日

研究注册日期

首次提交

2024年12月5日

首先提交符合 QC 标准的

2024年12月5日

首次发布 (实际的)

2024年12月9日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1497-0002
  • U1111-1308-7923 (注册表标识符:WHO International Clinical Trials Registry Platform (ICTRP))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD 共享时间框架

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

IPD 共享访问标准

For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅